+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07273721

Testing the Safety and Effectiveness of BT200 in Adults with Type 2B Von Willebrand Disease

Led by Medical University of Vienna · Updated on 2025-12-09

6

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of BT200 Rondaptivon Pegol, a new drug for patients with type 2B von Willebrand disease VWD who have low platelet counts and a history of bleeding. This phase 2 randomized clinical trial with a cross-over design involves 4 to 6 patients and is conducted at the Medical University of Vienna. The drug is expected to reduce the breakdown of von Willebrand factor VWF, potentially increasing VWF, platelet count, and factor VIII to reduce bleeding tendency. The study starts with an observation phase, followed by two treatment periods of about 64 days each. On day one, patients receive either BT200 or placebo by injection under the skin. Then, they self-administer 6 mg of BT200 or placebo once weekly for four weeks. After a washout period without treatment, patients switch to the other treatment for another four weeks with weekly injections. Follow-up visits occur during treatment periods, and a final clinic visit happens after the second washout phase. Participants may join an extension study after completion. During the study, researchers monitor platelet counts and clinically evident bleeding as primary outcomes, comparing treatment versus control phases. They also measure various von Willebrand factor activities, platelet function under high shear rates, BT200 levels in plasma, and record adverse events related to the drug. Participants complete all study procedures, including follow-ups and safety assessments, over the full study duration ending with the option of continuing in an extension phase.

CONDITIONS

Brief Title

Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease

Research Team

C

Christian Schörgenhofer, Principal Investigator, MD, PHD

B

Bernd Jilma, Subinvestigator, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here